5 results about "Targeted microbubbles" patented technology

Selective displacement of two or more distinct monodisperse targeted microbubble (tMB) populations presenting unique surface ligands by matching the incoming ultrasound frequency to the size-dependent resonance frequency of each tMB population thereby selecting their respective translations towards a target cell or tissue.

This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment.

The invention discloses a targeting microbubble for targeting microvascular endothelium as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The targeted microvesicle of the targeted microvascular endothelium provided by the invention comprises a biotinylated liposome microvesicle combined with streptavidin and a biotinylated carbonic anhydrase 4 antibody, the biotinylated liposome microbubble combined with streptavidin takes lipid as a shell membrane material, fluorinated inert gas is wrapped in the shell membrane material, and the surface of the shell membrane material is combined with streptavidin; and the shell membrane material is prepared from DSPC (Distearoyl Pyrrolidone), DSPE-PEG (Polyethylene Glycol) 2000 and DSPE-PEG 2000-biotin. The targeting microbubble has good targeting property, biocompatibility and safety, and can intuitively reflect the density difference of microvessels, thereby providing an intuitive and reliable imaging basis for early diagnosis and disease assessment of coronary artery microvascular diseases.

Described herein are pharmaceutical compositions containing genes encoding a positive regulatory domain zinc finger protein 16, a peroxisome proliferator-activated receptor gamma coactivator 1-alpha protein, and a bone morphogenetic protein 7. Also disclosed are methods of treating or managing obesity and diabetes by delivering these pharmaceutical compositions using ultrasound-targeted microbubble destruction.